Drug treatment of multiple sclerosis

Western Journal of Medicine

Volumn 173, Issue 6, 2000, Pages 398-402

  Polman, C H ^a   Uitdehaag, B M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RECOMBINANT BETA INTERFERON;

ARTICLE; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; RELAPSE; REMISSION;

EID: 0034522161     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: 10.1136/ewjm.173.6.398     Document Type: Article

References (28)

1. The natural history of multiple sclerosis
2. New insights into the immunogenetics of multiple sclerosis
3. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis
4. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis: US National MS Society Task Force
5. The role of magnetic resonance techniques in understanding and managing multiple sclerosis
6. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis
7. Methylprednisolone for acute relapses of multiple sclerosis: Can oral replace intravenous administration?
8. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
9. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
10. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I, clinical results of a multicenter randomized, double-blind, placebo-controlled trial
11. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group
12. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II, MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
13. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis
14. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing remitting multiple sclerosis
15. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): Design of the study
16. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
17. Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS study
18. Treatment of multiple sclerosis with interferon β: An appraisal of cost-effectiveness and quality of life
19. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): A multicenter, randomized, double-blind, placebo-controlled study extended by open label treatment
20. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
21. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis
22. Overview of azarhioprine treatment in multiple sclerosis
23. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
24. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives
25. Axonal transection in the lesions of multiple sclerosis
26. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
27. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
28. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: A study of 113 cases